# A Phase III Study of NK105 in Patients With Breast Cancer

> **NCT01644890** · PHASE3 · COMPLETED · sponsor: **Nippon Kayaku Co., Ltd.** · enrollment: 436 (actual)

## Conditions studied

- Breast Cancer Nos Metastatic Recurrent

## Interventions

- **DRUG:** NK105
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01644890
- **Lead sponsor:** Nippon Kayaku Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2016-07
- **Final completion:** 2017-01
- **Target enrollment:** 436 (ACTUAL)
- **Last updated:** 2019-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01644890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01644890, "A Phase III Study of NK105 in Patients With Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01644890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*